Gamma-ray emission for imaging

**Gamma-ray emission for imaging** refers to the use of *gamma photon emissions* from radioactive isotopes (radioisotopes) that are administered to a patient and subsequently detected by gamma cameras, SPECT, or PET systems[1][2][6][7]. These isotopes concentrate in specific organs or tissues, allowing visualization of physiological processes and abnormalities through external imaging devices. Gamma-ray emitting isotopes commonly used in diagnostic imaging include **technetium-99m**, **thallium-201**, and **fluorine-18** among others[1][3]. Gamma-ray emission is not a molecule, receptor, or cellular target, but a physical process harnessed for medical imaging, disease diagnosis (such as in oncology, cardiology, and neurology), and monitoring the effects of treatment[1][5][6]. The technology depends on detecting photons produced in the body as the radioisotope decays; these emissions are captured as two- or three-dimensional images revealing organ function, tissue metabolism, and abnormal growths (such as tumors)[1][2][6][7]. Gamma-ray emission does not have a biological or molecular function—it is central to the physical mechanism underlying nuclear medicine imaging technology. It is not a drug target, biomarker, nor does it participate directly in biological pathways. Instead, it enables visualization of physiological or pathological processes by tracking the distribution of radioactively labeled tracers within the body[1][2][6][7].

Other names

Gamma emission imagingGamma camera imagingSPECT imagingNuclear medicine imagingGamma radiation imaging